US EditionPfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
GREATER LONDON, ENGLAND, AUG 1 – The court confirmed Moderna's patent validity and Pfizer/BioNTech's infringement, with Pfizer planning to appeal to Britain’s Supreme Court, after a £19 million legal battle since 2020.
- On August 1, 2025, the Court of Appeal in London confirmed the legitimacy of Moderna’s EP'949 patent in its dispute with Pfizer and BioNTech.
- This ruling follows the July 2024 High Court judgment which upheld the legitimacy of Moderna’s patent and determined that Pfizer and BioNTech’s COVID-19 vaccine, Comirnaty, violated it—a decision that Pfizer and BioNTech challenged on appeal.
- The appeal dismissal forms part of a broader multi-million pound legal battle involving cases in the US, Germany, Belgium, the Netherlands, and Ireland, with a German court also ruling Pfizer and BioNTech violated a related Moderna patent.
- Moderna welcomed the ruling and affirmed its commitment to protecting its mRNA technology patents worldwide, while Pfizer maintained that the patent is invalid and announced it will take the matter to the UK Supreme Court.
- Friday's ruling enhances Moderna's patent standing and may influence ongoing legal battles among major pharmaceutical companies, while leaving Pfizer and BioNTech's current position unchanged.
10 Articles
10 Articles
Pfizer, BioNTech Lose Appeal in COVID–19 Vaccine Patent Battle With Moderna
U.S. pharmaceutical giant Pfizer and German firm BioNTech lost a court appeal on Friday, August 1st, in the latest step of a multi-million-pound battle against U.S. rival Moderna over the COVID–19 vaccine. The UK Court of Appeal found that one of the European patents held by Moderna was invalid, but that a second one had been infringed by Pfizer and its partner BioNTech. “The judge made no error of law or principle” in the ruling handed down in …
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna’s patents at London’s Court of Appeal. Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in re…
Denver Gazette
Weatherford DemocratUK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.
London: The most recent rounds of its battle worth millions of pounds sterling have been lost by a company that competed to develop a vaccine against Coved-19. The long-term dispute, in which American and German piontech competed against Moderna, is centred on the use of ribose DNA technology in life-saving vaccines. Last July, [...]
Coverage Details
Bias Distribution
- 33% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
